A5088309447- Reliability and Agreement in Measurement
- Prostate Cancer Diagnosis and Treatment
- Ultrasound and Hyperthermia Applications
- Cancer Immunotherapy and Biomarkers
- Infrared Thermography in Medicine
- Venous Thromboembolism Diagnosis and Management
- CAR-T cell therapy research
- Regulation of Appetite and Obesity
- Spacecraft Design and Technology
- Colorectal Cancer Treatments and Studies
- Adipokines, Inflammation, and Metabolic Diseases
- Spaceflight effects on biology
- Space Exploration and Technology
- Hemodynamic Monitoring and Therapy
- Occupational and environmental lung diseases
- Lung Cancer Diagnosis and Treatment
- Prostate Cancer Treatment and Research
- Meta-analysis and systematic reviews
- Nutrition and Health in Aging
- Health and Medical Research Impacts
- Radiomics and Machine Learning in Medical Imaging
- Frailty in Older Adults
- Body Composition Measurement Techniques
- Effects of Radiation Exposure
- Pleural and Pulmonary Diseases
Ono Pharmaceutical (Japan)
2020-2024
Jikei University School of Medicine
2000-2009
Abstract Background Anamorelin was approved in Japan 2021 to treat cancer cachexia associated with non‐small cell lung, gastric, pancreatic, or colorectal cancers. Post‐marketing surveillance is being conducted evaluate the real‐world safety and effectiveness of anamorelin. Methods This prospective, observational registered all patients who started treatment anamorelin after April 21, 2021. Hyperglycemia, hepatic impairment, conduction disorders, their adverse events related were defined as...
Abstract Background Cohen’s κ coefficient is often used as an index to measure the agreement of inter-rater determinations. However, varies greatly depending on marginal distribution target population and overestimates probability occurring by chance. To overcome these limitations, alternative more stable was proposed, referred Gwet’s AC 1 . When it desired combine results from multiple studies, such in a meta-analysis, or perform stratified analysis with subject covariates that affect...
Abstract Background Nivolumab has been approved for treating ≥ 10 cancer types. However, there is limited information on the incidence of rare, but potentially serious, treatment-related adverse events (TRAEs), as well notable TRAEs in patients with certain medical disorders or older Japan. Methods We performed pooled analyses data from published post-marketing surveillance Japan nivolumab monotherapy malignant melanoma, non-small cell lung cancer, renal carcinoma, head and neck gastric to...
This post-marketing surveillance (PMS) was conducted to evaluate the incidence of adverse events with nivolumab in patients unresectable, advanced or recurrent malignant pleural mesothelioma (MPM) that had progressed after first-line chemotherapy and identify factors potentially affected its safety real-world clinical practice.
薬学・生命科学の進歩に伴い,創薬研究者に求められる統計学の素養も日増しに高まっている.創薬に関わる,あるいはこれから関わろうとしている研究者に対して,創薬研究を円滑に進めるための統計教育が必要である.筆者は,創薬研究者の統計的思考力を高めることにより,研究目的に沿った合理的な実験計画の立案力がつくだけでなく,創薬イノベーションや研究競争力強化の一助になると考えている.本稿では,筆者の所属する企業における非臨床分野の統計教育事例を紹介する.そのなかで,創薬ターゲット選定,リード物質探索などの創薬の初発研究から非臨床試験,品質試験など,いわゆる非臨床分野に携わる統計家と創薬研究者のかかわりや,創薬研究者が抱えている統計学での悩み,統計的思考力を高める人財育成の展望についても論じる.